Dr Roger Yazbek 

Multinational Association for Supportive Care in Cancer (MASCC)

Australian Society for Medical Research (ASMR)

International Proteolysis Society (IPS)

Gastroenterological Society of Australia (GESA)

2005-2009: PhD, Thesis: Dipeptidyl Peptidase Inhibitors: A Novel Therapeutic Strategy for Inflammatory Bowel Disease, Flinders University

2004: Bachelor of Science (Honours), Flinders University

2001-2003: Bachelor of Science, The University of Adelaide

Gibson RJ, Keefe DM, Lalla RV, Bateman E, Blijlevens N, Fijlstra M, King EE, Stringer AM, van der Velden WJ, Yazbeck R, Elad S, Bowen JM; Systematic review of agents for the management of gastrointestinal mucositis in cancer patients, Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO), Support Care Cancer, 2013 Jan;21(1):313-26, 2012 Nov 10

Yazbeck R, Dawson P, Rogers N, West C, Keogh R, Wallace D, Polyak S, Nowak K, Burt R, Taylor J, Dunn L, Philp A, Parkinson-Lawrence E, Indigenous Health: ACTION on Prevention - 50th annual Australian Society for Medical Research National Scientific Conference, Rural Remote Health. 2012;12:2256, Epub 2012

Yazbeck R, Howarth GS, Borges L, Geier MS, Smith CL, Davidson GP, Butler RN, Non-invasive detection of a Palifermin-mediated adaptive response following chemotherapy-induced damage to the distal small intestine of rats, Cancer Biol Ther, 2011

Yazbeck R, Howarth GS, Butler RN, Geier MS, Abbott CA, Biochemical and Histological Changes in the Small Intestine of Mice with Dextran Sulfate Sodium Colitis, J Cell Physiol. 2011

Yazbeck R, Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome, Curr Opin Mol Ther 2010, 12(6):798-809 (This was also published online in the Thomson Reuters Drug Profiles database)

Yazbeck R, Howarth GS, Abbott CA. The use of glucagon-like factor-2 (GLP-2) and related growth factors in intestinal diseases. Curr Opin Invest Dr 2010;11(4):440-6

Lindsay RJ, Geier MS, Yazbeck R, and Howarth GS. Orally administrated emu oil decreases acute inflammation and alters selected parameters of small intestinal integrity in a rat model of mucositis. Brit J Nutr, 2010; 104(4):513-519

Whitford EJ, Cummins AG, Butler RN, Prisciandaro LD, Fauser JK, Yazbeck R, Lawrence A, Cheah KY, Wright TH, Lymn KA, Howarth GS. Streptococcus thermophilus TH-4 reduces intestinal crypt fission in rats treated with 5-Fluorouracil (5-FU). Cancer Biol Ther 2009; 8(6)

Cheah KY, Howarth GS, Yazbeck R, Wright TH, Whitford EJ, Payne C, Butler RN, Bastian SE. Grape seed extract protects IEC-6 cells from chemotherapy-induced cytotoxicity and improves parameters of small intestinal mucositis in rats with experimentally-induced mucositis. Cancer Biol Ther. 2009; 8(4):382-90

Wright TH, Yazbeck R, Lymn KA, Whitford EJ, Cheah KY, Butler RN, Feinle-Bisset C, Pilichiewicz AN, Mashtoub S, Howarth GS. The herbal extract, Iberogast®, improves jejunal integrity in rats with 5-Fluorouracil (5-FU)-induced mucositis. Cancer Biol Ther. 2009; 8(10):923-29

Roberts AL, Howarth GS, Liaw WC, Moretta S, Kritas S, Lymn KA, Yazbeck R, Tran C, Fletcher JM, Butler RN, Byers S. Gastrointestinal pathology in a mouse model of mucopolysaccharidosis type IIIA, J Cell Physiol. 2009; 219(2):259-64

Yazbeck R, Sulda ML, Howarth GS, Bleich A, Raber K, von Horsten S, Holst JJ, Abbott CA, Dipeptidyl Peptidase expression during experimental colitis in mice, Inflamm Bowel Dis. 2009; 16(8):1340-1351

Yazbeck R, Howarth GS, Complementary medicines: emerging therapies for intestinal mucositis, Cancer Biol Ther. 2009; 8(17):1629-31

Yazbeck R, Howarth GS, Abbott CA. Growth factor based therapies and intestinal disease: Is glucagon-like peptide-2 the new way forward? Cytokine Growth Factor Rev 2009; 20(2):175-84

Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?, Trends Pharmacol Sci 2009; 30(11): 600-07

Smith CL, Geier MS, Yazbeck R, Torres DM, Butler RN, Giffard PM, Turner MS, Howarth GS, Lactobacillus fermentum BR11 and Fructo-oligosaccharide Partially Reduce Jejunal Inflammation but not Overall Damage Severity of 5-FU-Induced Mucositis in Rats, Nutr Cancer. 2008; 60(6):757-767

Yazbeck R, Howarth GS, Geier MS, Demuth, HU, Abbott CA. Inhibition of dipeptidyl peptidase activity partially ameliorates development of experimentally-induced colitis in mice. Front Biosci. 2008

Geier MS, Abbott CA, Tenikoff D, Yazbeck R, McCaughan GW, Howarth GS. Development and Resolution of Experimental Colitis in Dipeptidyl Peptidase IV Knockout Mice. J Cell Physiol. 2005; 204(2):687-92

Abbott CA, Yazbeck R, Geier MS, Demuth HU and Howarth GS. Dipeptidyl peptidases and inflammatory bowel disease. Dipeptidyl Aminopeptidases Basic Science and Clinical Applications Series: Advances in Experimental Medicine and Biology, Vol. 575, U Lendeckel, D Reinhold Eds. ISBN: 0-387-29058-3. Springer NY, 33-42 (2006)